The flagship programme reviews selected cellular therapies, China-origin oncology medicines, biomarker-led options, and research pathways without treating novelty as proof of suitability or superiority.
The exact diagnosis, disease status, prior treatment, biomarkers, performance status, goals, alternatives, hospital team, complications, funding, and home continuity remain controlling.
For blood cancers, review begins with the exact diagnosis, disease status, antigen target, prior therapy, product or protocol, manufacturing route, bridging plan, lymphodepletion, toxicity readiness, and accepting home haematologist.
China-origin oncology medicines, biomarker-led options, cellular therapies, off-label use, sponsor-led trials, and investigator-led studies are classified separately before any hospital approach.
Satri-cel is presented as a narrowly labelled approved example, not evidence that CAR-T is established across solid tumours.
Oncological surgery and radiotherapy remain available when they are part of a clinically justified plan, with exact procedure or dose, named team, rescue capability, written quotation, and return-home records.
The case plan includes progression before travel, manufacturing or scheduling delay, treatment change, prolonged stay, ICU, rehabilitation, discharge, fitness to fly, complete records, and an accepting clinician at home.
The public form collects only a short, non-identifying overview. Detailed oncology records require a secure consented process.